166 related articles for article (PubMed ID: 19541584)
1. Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease.
Kastenbauer U; Wolf E; Kollan C; Hamouda O; Bogner JR;
Eur J Med Res; 2009 Jun; 14(6):244-9. PubMed ID: 19541584
[TBL] [Abstract][Full Text] [Related]
2. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection.
Mansharamani NG; Balachandran D; Vernovsky I; Garland R; Koziel H
Chest; 2000 Sep; 118(3):712-20. PubMed ID: 10988193
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.
Costiniuk CT; Fergusson DA; Doucette S; Angel JB
PLoS One; 2011; 6(12):e28570. PubMed ID: 22194853
[TBL] [Abstract][Full Text] [Related]
5. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection.
Enomoto T; Azuma A; Kohno A; Kaneko K; Saito H; Kametaka M; Usuki J; Gemma A; Kudoh S; Nakamura S
Respirology; 2010 Jan; 15(1):126-31. PubMed ID: 19947989
[TBL] [Abstract][Full Text] [Related]
6. [Pneumocystis jiroveci pneumonia characteristics in adults with AIDS with or without antiretroviral therapy].
Bahamondes M L; Villar Z MJ; Orellana C C; González R J; Montenegro U C
Rev Chilena Infectol; 2006 Sep; 23(3):215-9. PubMed ID: 16896493
[TBL] [Abstract][Full Text] [Related]
7. Toxoplasma encephalitis in an HIV-infected patient on highly active antiretroviral therapy despite sustained immune response.
Atreya AR; Arora S; Gadiraju VT; Martagon-Villamil J; Skiest DJ
Int J STD AIDS; 2014 Apr; 25(5):383-6. PubMed ID: 24108450
[TBL] [Abstract][Full Text] [Related]
8. [Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994].
Bossi P; Caumes E; Astagneau P; Li TS; Paris L; Mengual X; Katlama C; Bricaire F
Rev Med Interne; 1998 May; 19(5):313-7. PubMed ID: 9775164
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
Opravil M; Hirschel B; Lazzarin A; Heald A; Pechère M; Rüttimann S; Iten A; von Overbeck J; Oertle D; Praz G
Clin Infect Dis; 1995 Mar; 20(3):531-41. PubMed ID: 7756472
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
[TBL] [Abstract][Full Text] [Related]
11. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Antinori A; Murri R; Ammassari A; De Luca A; Linzalone A; Cingolani A; Damiano F; Maiuro G; Vecchiet J; Scoppettuolo G
AIDS; 1995 Dec; 9(12):1343-50. PubMed ID: 8605054
[TBL] [Abstract][Full Text] [Related]
12. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine.
Köppen S; Grünewald T; Jautzke G; Gottschalk J; Pohle HD; Ruf B
Clin Investig; 1992 Jun; 70(6):508-12. PubMed ID: 1356529
[TBL] [Abstract][Full Text] [Related]
14. Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).
Schäfer G; Hoffmann C; Arasteh K; Schürmann D; Stephan C; Jensen B; Stoll M; Bogner JR; Faetkenheuer G; Rockstroh J; Klinker H; Härter G; Stöhr A; Degen O; Freiwald E; Hüfner A; Jordan S; Schulze Zur Wiesch J; Addo M; Lohse AW; van Lunzen J; Schmiedel S;
AIDS Res Ther; 2019 Nov; 16(1):34. PubMed ID: 31729999
[TBL] [Abstract][Full Text] [Related]
15. Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial.
Qin Y; Lu Y; Zhou Y; Harypursat V; Sun F; Yang S; Tang S; Li Y; He X; Zeng Y; Chen Y
Trials; 2020 Jun; 21(1):551. PubMed ID: 32571429
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
[TBL] [Abstract][Full Text] [Related]
17. Immune reconstitution inflammatory syndrome associated with toxoplasmic encephalitis in HIV-infected patients.
van Bilsen WPH; van den Berg CHSB; Rijnders BJA; Brinkman K; Mulder JW; Gelinck LBS; Hoepelman AIM; Wit FWNM; van de Beek D; Prins JM
AIDS; 2017 Jun; 31(10):1415-1424. PubMed ID: 28375874
[TBL] [Abstract][Full Text] [Related]
18. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
[TBL] [Abstract][Full Text] [Related]
19. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
20. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
